Nanobiotix SA Sponsored ADR NBTX 深 沪
等待开盘 03-27 09:30:00 美东时间
31.32
+0.690
+2.25%
华盛通- 最 高41.8899
- 今 开30.56
- 成交量 6.81万股
- 最 低 28.395
- 昨 收 30.63
- 总市值 109.23万
- 52周最高 41.8899
- 市盈率 静 --
- 换手率 195.22%
- 52周最低 2.9855
- 委 比 50.00%
- 总股本 3.49万
- 历史最高 41.8899
- 量 比 0.94
- 振 幅 44.06%
- 历史最低 0.00
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process
Nanobiotix rejects takeover talk after J&J speculation; stock jumps as analysts weigh momentum strength against mixed technical signals.
03-26 01:02
Looking Into Nanobiotix SA's Recent Short Interest
Nanobiotix SA's (NYSE:NBTX) short interest as a percent of float has risen 22.2...
01-22 23:00
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
Nanobiotix's management will participate in fireside chats at the Jefferies Global Healthcare Conference on June 5, 2025, at 3:45 pm EDT in New York. The event will be live webcast and available for replay.
2025-05-28 06:00
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
Nanobiotix reports first patient dosed in the Phase 2 CONVERGE study for unresectable stage 3 NSCLC and presents clinical data supporting further expansion of JNJ-1900 (NBTXR3) in lung cancer and pancreatic cancer. Additionally, the company strengthened its financial position through an amended licensing agreement, extending cash runway into mid-2026, with €39.8 million in cash and cash equivalents as of March 31, 2025.
2025-05-21 20:15
NANOBIOTIX Reports H1 Basic EPS Of €(0.46), Up From €(0.80) Last Year, Revenue And Other Income Of €9.3M, Up From €3.3M Last Year
Net loss attributable to common shareholders for the six months ended June 30, 2024, was €21.9 million, or a €0.46 basic loss per share. This compares to a net loss attributable to common shareholders of
2024-09-19 04:24
Guggenheim Initiates Coverage On Nanobiotix with Buy Rating, Announces Price Target of $12
Guggenheim analyst Michael Schmidt initiates coverage on Nanobiotix (NASDAQ:NBTX) with a Buy rating and announces Price Target of $12.
2024-08-28 19:27
--Guggenheim Initiates Nanobiotix at Buy
05:39 AM EDT, 08/28/2024 (MT Newswires) -- Nanobiotix S.A (NBTX) has an average rating of buy and price targets ranging from $10 to $16, according to analysts outperform by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, ...
2024-08-28 17:39
